Provinces agree to fund Hemlibra for inhibitor patients
Montreal, June 13, 2019 – Canadian Blood Services has announced the availability of Hemlibra (emicizumab injection) for individuals with hemophilia A and inhibitors.
Click on the link below to read the message sent to CHS President, Paul Wilton.
2018 Annual Report
We are proud of our accomplishments for 2018. Click on the link to read all about those accomplishments and more.
Hemlibra available to Quebec patients with hemophilia A and inhibitors
May 9, 2019 – Montreal – Héma-Québec informed the Canadian Hemophilia
Society-Quebec Chapter (CHSQ) today that Hemlibra® will be available for the
treatment of patients with hemophilia A and inhibitors in Quebec in the coming
days.
Access to Eloctate
On February 24, the CHS Board of Directors formally objected to the recent CBS decision to restrict access to Eloctate for children under 12 and called on the CBS to reverse its decision.
Research - Recruiting
Are there inequities in access to care amongst certain groups of patients with bleeding disorders?
St. Michael’s Hospital is conducting a study on access to care, in collaboration with the Canadian Hemophilia Society. People 18 years and older with a bleeding disorder are being asked to consider participating.
Latest development re the Pre-1986/Post-1990 Hepatitis C Settlement Agreement
On October 16-17, 2019, an application will be made by Class Counsel to the Justices overseeing the pre-1986/post-1990 Hepatitis C Class Action. At the Application Class Counsel will be seeking orders for:
- A declaration that future payments out of the Past Economic Loss and Dependents Fund shall be in a manner to be determined by the courts at this hearing.
- Such further and other relief as the Honourable Courts may deem just.
More information for those wishing to make submissions and with respect to the locations for the hearing and the start times will be provided shortly at www.pre86post90settlement.ca.
Recombinant factor concentrate charts
Please check out our updated charts listing the recombinant factor concentrates and their description.
